NIVF NewGenIvf Group Ltd Annual reports only
Services-Misc Health & Allied Services, NEC · Nasdaq · SEC CIK 1981662
Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year
Growth
TTM revenue YoY-13.0%
TTM net income YoY1,983.1%
TTM EPS YoY100.1%
Revenue 3-yr CAGR-7.4%
Net income 3-yr CAGR178.2%
Margins
Gross margin20.2%
Operating margin-226.9%
Net margin209.0%
FCF margin-234.0%
EBITDA margin-223.0%
Returns
ROE77.2%
ROA54.4%
ROIC (approx.)-88.0%
Asset turnover0.26x
Leverage & solvency
Liabilities / assets20.6%
Debt / equity0.00x
Current ratio3.12x
Interest coverage-17.40x
Cash quality & payout
Operating cash flow / net income-1.11x
Accruals ratio114.6%
Payout ratio—
Capex / revenue2.9%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $4.73M | $5.43M | $5.14M | $5.94M | $4.12M |
| Cost of revenue | $3.77M | $3.61M | $3.45M | $4.41M | $3.09M |
| Gross profit | $955,846 | $1.83M | $1.68M | $1.54M | $1.02M |
| SG&A expense | $10.49M | $2.78M | $1.62M | $1.10M | $801,329 |
| Operating income | -$10.73M | -$1.16M | $42,242 | $398,705 | $198,758 |
| Interest expense | $616,423 | $765,177 | $46,179 | — | — |
| Pretax income | $9.73M | -$960,807 | $108,418 | $343,988 | $156,184 |
| Income tax | — | -$486,706 | — | $208,141 | $294,716 |
| Net income | $9.88M | -$524,643 | $130,193 | $458,667 | -$533 |
| EBITDA | -$10.54M | -$1.14M | $73,415 | $499,238 | $365,467 |
| EPS (basic) | 214.73 | -4,408.76 | 13,019.30 | 4.72 | 0.00 |
| EPS (diluted) | 3.04 | -4,408.76 | 13,019.30 | 4.72 | 0.00 |
| Weighted avg. shares (diluted) | 3.25M | 119 | 10 | 28,797 | 560,000 |
| Banking | |||||
| Provision for credit losses | — | $17,818 | — | — | — |
| Balance sheet | |||||
| Cash & equivalents | $758,621 | $457,740 | $54,104 | $27,556 | $28,764 |
| Receivables | $166,531 | $49,245 | $9,374 | $13,000 | — |
| Inventory | $335,360 | $80,813 | $126,264 | $46,910 | — |
| Current assets | $7.38M | $3.17M | $2.46M | $2.40M | — |
| PP&E, net | $1.79M | $273,096 | $162,157 | $122,673 | — |
| Intangibles | $21.42M | — | — | — | — |
| Total assets | $32.72M | $3.58M | $4.49M | $2.90M | — |
| Current liabilities | $2.37M | $2.72M | $1.12M | $2.56M | — |
| Total liabilities | $6.74M | $5.06M | $1.24M | $2.80M | — |
| Shareholders' equity | $26.63M | -$1.05M | $3.74M | $563,113 | -$914,910 |
| Shares outstanding | 240,622 | 380 | 507,469 | 601,830 | — |
| Cash flow statement | |||||
| Operating cash flow | -$10.93M | -$8.26M | -$1.77M | $1.71M | $1.43M |
| Capital expenditure | $135,025 | $53,045 | $69,848 | $94,452 | $16,575 |
| Free cash flow | -$11.06M | -$8.32M | -$1.84M | $1.62M | $1.42M |
| Investing cash flow | -$7.56M | -$53,045 | -$69,848 | -$94,452 | -$16,575 |
| Financing cash flow | $18.99M | $8.68M | $1.88M | -$1.63M | -$1.54M |
| Depreciation & amortization | $188,109 | $19,502 | $31,173 | $100,533 | $166,709 |
| Stock-based compensation | — | — | — | $240,000 | $200,000 |
· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.